Tag: Atara Biotherapeutics

December 17, 2018

Atara Biotherapeutics Presents Positive Efficacy and Safety Results for Patients with Epstein-Barr Virus-Associated Leiomyosarcoma

Atara Biotherapeutics (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral...
November 30, 2018

Atara Biotherapeutics Highlights Next-Generation and Off-the-Shelf, Allogeneic CAR T Technologies and Pipeline

Atara Biotherapeutics (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral...
November 19, 2018

Atara Biotherapeutics Releases Published Clinical Results

The results are for a Phase 1 clinical study of ATA190, an autologous EBV-specific T-cell immunotherapy in development for multiple...
November 19, 2018

Atara Biotherapeutics Announces Publication of Phase 1 Study Demonstrating Clinical Improvement

Atara Biotherapeutics (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral...
September 6, 2018

Atara Biotherapeutics and Moffitt Cancer Center Announce Strategic Collaboration to Develop Next-Generation CAR T Immunotherapies

Atara Biotherapeutics (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral...
February 28, 2018

Atara Biotherapeutics Announces Proposed Offering of Common Stock

Atara Biotherapeutics (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases,...
February 27, 2018

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Recent Operational Progress

Atara Biotherapeutics (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases,...